2013, Number 3
<< Back Next >>
Rev Cent Dermatol Pascua 2013; 22 (3)
Quality of life in men with melasma
Jurado SF, Villaseñor CGP, Peralta PML, Rodríguez AM, Morales SM
Language: Spanish
References: 14
Page: 94-99
PDF size: 211.26 Kb.
ABSTRACT
Background: Melasma is a facial dermatosis characterized by the presence of hyperchromic, well limited spots. Previous studies have demonstrated that melasma affects the quality of life of those who suffer it. In our country, data does not exist about the impact in the quality of life in men.
Objective: To determine the quality of life in men with melasma, and to compare with a control group.
Material and methods: There was realized a transverse, comparative study in the Dermatological Center Dr. «Ladislao de la Pascua». Two groups of patients were recruited: men with melasma and a control group without dermatological diseases. There were applied to them the quality of life questionnaires SF-36 and Melasma Quality of Life Scale.
Results: Eigthy men with melasma and 50 controls were studied. The average of the total scale of the questionnaire SF-36 was 73.9 in the group of cases and 78.8 in the controls (p = 0.099). The scale in the dimension of general health was different in both groups (p = 0.003). Patients showed more impact in the quality of life in the items of appearance, frustration, inconvenience and on having felt less attractive according to the questionnaire Melasma Quality of Life Scale.
Conclusion: Men with melasma have 1.5 more risk of diminishing his quality of life in comparison with men without dermatological diseases.
REFERENCES
Grimes P. Melasma, Etiologic and Therapeutic Considerations. Arch Dermatol. 1995; 131: 1447-1452.
Victor FC, Gelber J, Rao B. Melasma: a review. J Cutan Med Surg. 2004; 8: 97-102.
Vázquez M, Maldonado H, Benaman C, Sánchez JL. Melasma in men: a clinical and histological study. Int J Dermatol. 1988; 27: 25-27.
Sarkar R, Puri P, Jain RK, Singh A, Desai A. Melasma in men: a clinical, aetiological and histological study. J Eur Acad Dermatol Venereol. 2010; 24: 768-772.
Pichardo R, Vallejos Q, Feldman SR, Schulz MR, Verma A, Quandt SA, Acury TA. The prevalence of melasma and its association with quality of life among adult male migrant latino workers. Int J Dermatol. 2009; 48: 22-26.
Balkrishnan R, McMichale AJ, Camacho FT, Saltzberg F, Housman TS, Grummer S, Feldman SR, Chren MM. Development and validation of a health-related quality instrument for women with melasma. Br J Dermatol. 2003; 149: 572-577.
Zúñiga MA, Carrillo-Jiménez GT, Fos PJ, Gandek B, Medina-Moreno MR. Evaluación del estado de salud con la Encuesta SF-36: resultados preliminares en México. Salud Publica Mex. 1999; 41: 110-118.
Ware J, Keller S, Gandek B, Brazier J, Sullivan M, the IQOLA Project Group. Evaluating translation of health status questionnaires: Methods from the IQOLA Project. Int J Technol Assess Health Care. 1995; 11: 525-551.
Domínguez AR, Balkrishnan R, Ellzey AR, Pandya AG. Melasma in latina patients: Cross-cultural adaptation and validation of a quality-of-life questionnaire in Spanish language. J Am Acad Dermatol. 2006; 55: 59-66.
Lieu TJ, Pandya AG. Melasma quality of life measures. Dermatol Clin. 2012; 30: 269-280.
Pichardo R, Vallejos Q, Feldman SR, Schulz MR, Verma A, Quandt SA, Arcury TA. The prevalence of melasma and its association with quality of life among adult male migrant latino workers. Int J Dermatol. 2009; 48: 22-26.
Freitag FM, Cestari TF, Leopoldo LR, Paludo P, Boza JC. Effect of melasma on quality of life in a simple of women living in southern Brazil. JEADV. 2008; 22: 655-662.
Ali R, Aman S, Nadeem M, Kazmi AH. Quality of life in patients of melasma. J Pakistan Association of Dermatologists. 2013; 23: 143-148.
Cestari TF, Hexsel D, Viegas ML, Azulay L, Hassun K, Almeida ART, Rego VRPA, Mendes AMD, FilhossWA, Junqueira H. Validation of a melasma quality of life questionnaire for Brazilian Portuguese language: the MelasQoL-BP study and improvement of QoL of melasma patients after triple combination therapy. Br J Dermatol. 2007; 156 (supl 1): 13-20.